PURPOSE: To describe treatment of chronic Irvine-Gass syndrome (CME) with interferon (IFN) alpha. METHODS: Interventional retrospective case series. IFN alpha-2a was administered at a dose of 3 million IU/day subcutaneously for 4 weeks, and was tapered thereafter. Treatment efficacy was assessed by best-corrected visual acuity (BCVA) and by optical coherence tomography (OCT). RESULTS: Three patients (4 eyes) with chronic Irvine-Gass syndrome were treated. Ineffective pretreatment included local and systemic corticosteroids. Within 4 weeks, IFN alpha led to resolution of CME in all eyes. BCVA improved in 3 eyes and remained unchanged in 1 eye. During follow-up of 3-11 months no relapse of CME occurred. No systemic or local side effects were noted. CONCLUSIONS: IFN alpha has been demonstrated to be a successful and well-tolerated treatment option for resistant chronic pseudophakic CME. Further studies are necessary to evaluate the role of IFN alpha in Irvine-Gass syndrome.
PURPOSE: To describe treatment of chronic Irvine-Gass syndrome (CME) with interferon (IFN) alpha. METHODS: Interventional retrospective case series. IFN alpha-2a was administered at a dose of 3 million IU/day subcutaneously for 4 weeks, and was tapered thereafter. Treatment efficacy was assessed by best-corrected visual acuity (BCVA) and by optical coherence tomography (OCT). RESULTS: Three patients (4 eyes) with chronic Irvine-Gass syndrome were treated. Ineffective pretreatment included local and systemic corticosteroids. Within 4 weeks, IFN alpha led to resolution of CME in all eyes. BCVA improved in 3 eyes and remained unchanged in 1 eye. During follow-up of 3-11 months no relapse of CME occurred. No systemic or local side effects were noted. CONCLUSIONS:IFN alpha has been demonstrated to be a successful and well-tolerated treatment option for resistant chronic pseudophakic CME. Further studies are necessary to evaluate the role of IFN alpha in Irvine-Gass syndrome.
Authors: Brandon Huy Pham; Doan Luong Hien; Wataru Matsumiya; Than Trong Tuong Ngoc; Huy Luong Doan; Amir Akhavanrezayat; Çigdem Yaşar; Huy Vu Nguyen; Muhammad Sohail Halim; Quan Dong Nguyen Journal: Am J Ophthalmol Case Rep Date: 2020-08-20